原发性卵巢癌肉瘤16例临床分析

发布时间：2019-02-12 13:35

【摘要】：目的:卵巢癌肉瘤,不同于一般的卵巢恶性肿瘤,它的发病率低,约占卵巢恶性肿瘤的1%-2%,但恶性程度高,病人发病的时候,大部分已属晚期;该病易复发,预后差,目前还没有统一的明确的治疗方案,本临床分析通过对该病症状、体征、实验室检查、影像学特点、病理特点、治疗方案、影响预后因素进行探讨,为卵巢癌肉瘤的诊断、治疗提供参考。方法:对1997-2017年于广西医科大学附属肿瘤医院就诊的13例以及玉林市肿瘤医院1例,玉林市第一人民医院1例,柳州市肿瘤医院1例,共16例原发性卵巢癌肉瘤患者的临床表现、实验室检查、影像学特点、病理特点、治疗方案、影响预后因素等进行回顾性分析。用SPSS17.0统计学软件进行Kaplan-Meier法生存分析,Log rank检验比较生存差异,Cox回归模型进行多变量分析,各分析检验方法中以p0.05认为有统计学意义。结果:1例失访、9例死亡,其生存期分别是:2、2.5、3.6、3.7、5、12、24.4、40、45、61个月;至末次随访,6例存活,其生存期分别是:4.5、7、11.2、22.8、26、46个月。总体1、2、5年生存率分别是50%、37.5%、6.25%。I/Ⅱ期1、2、5年生存率分别是87.5%、62.5%、12.5%;Ⅲ/Ⅵ期1、2、5年生存率分别是12.5%、12.5%、0。单因素分析及多因素分析显示,临床分期、术后化疗是卵巢癌肉瘤独立的预后因素。结论:1、卵巢癌肉瘤是一种发病率低、恶性程度高、易转移、易复发、预后差的肿瘤。2、卵巢癌肉瘤多发生于绝经后女性,多伴有CA125的升高,影像学表现为盆腔包块,多数伴有腹水。3、卵巢癌肉瘤主要治疗方法是:肿瘤细胞减灭术+含铂类药物为基础的化疗。4、临床分期、术后化疗是影响卵巢癌肉瘤患者预后的独立因素。
[Abstract]:Objective: ovarian cancer sarcoma, which is different from the common ovarian malignant tumor, has a low incidence, accounting for 1- 2 percent of the ovarian malignant tumor, but has a high degree of malignancy. The disease is easy to recur and poor prognosis. There is no unified and definite treatment plan at present. This clinical analysis discussed the symptoms, signs, laboratory examination, imaging features, pathological features, treatment plan and influencing factors of prognosis. To provide reference for diagnosis and treatment of ovarian cancer sarcoma. Methods: from 1997 to 2017, 13 patients in the affiliated Cancer Hospital of Guangxi Medical University, 1 patient in Yulin City tumor Hospital, 1 case in the first people's Hospital of Yulin City and 1 case in Liuzhou Cancer Hospital were studied. The clinical manifestations, laboratory examination, imaging features, pathological features, therapeutic schemes and prognostic factors of 16 patients with primary ovarian cancer sarcoma were retrospectively analyzed. The survival difference was compared by Kaplan-Meier survival analysis, Log rank test with SPSS17.0 statistical software and multivariate analysis with Cox regression model. Results: one case lost the visit, 9 cases died, the survival time was 22.5U 3.6C 3.7U 3.7U 5.1224.4L 4045,61 months, and at the last follow-up, 6 cases survived, the survival time was 4.5U 711.2U 22.8t 26and 46 months respectively. The overall 1 / 2 and 5 year survival rates were 50% and 6. 25% respectively, and the 5 year survival rates were 87.5% (62.5%) and 12.5% (P < 0 05), respectively. The 2-and 5-year survival rates of stage 鈪，

本文编号：2420483